231 related articles for article (PubMed ID: 30192930)
1. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis.
Dahl Aarvik M; Sandven I; Dondo TB; Gale CP; Ruddox V; Munkhaugen J; Atar D; Otterstad JE
Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):12-20. PubMed ID: 30192930
[TBL] [Abstract][Full Text] [Related]
2. Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With Preserved Systolic Function? A Meta-Analysis.
Misumida N; Harjai K; Kernis S; Kanei Y
J Cardiovasc Pharmacol Ther; 2016 May; 21(3):280-5. PubMed ID: 26424094
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis.
Maqsood MH; Alam M; Atar D; Birnbaum Y
J Cardiovasc Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 33136764
[TBL] [Abstract][Full Text] [Related]
4. Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study.
Mohammad MA; Andell P; Koul S; Desta L; Jernberg T; Omerovic E; Spaak J; Fröbert O; Jensen J; Engstrøm T; Hofman-Bang C; Persson H; Erlinge D
EuroIntervention; 2017 Jun; 13(2):e210-e218. PubMed ID: 28242589
[TBL] [Abstract][Full Text] [Related]
5. The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics.
Kristensen AMD; Munkhaugen J; Halvorsen S; Olsen MH; Bakken A; Sehested TSG; Ruddox V; Lange T; Fagerland MW; Torp-Pedersen C; Prescott E; Atar D
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):175-183. PubMed ID: 38017624
[TBL] [Abstract][Full Text] [Related]
6. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases.
Neumann A; Maura G; Weill A; Alla F; Danchin N
Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004356. PubMed ID: 29653999
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral beta-blocker therapy on mortality after primary percutaneous coronary intervention for Killip class 1 myocardial infarction.
Hioki H; Motoki H; Izawa A; Kashima Y; Miura T; Ebisawa S; Tomita T; Miyashita Y; Koyama J; Ikeda U
Heart Vessels; 2016 May; 31(5):687-93. PubMed ID: 25863805
[TBL] [Abstract][Full Text] [Related]
8. Perioperative beta-blockers for preventing surgery-related mortality and morbidity.
Blessberger H; Kammler J; Domanovits H; Schlager O; Wildner B; Azar D; Schillinger M; Wiesbauer F; Steinwender C
Cochrane Database Syst Rev; 2014 Sep; (9):CD004476. PubMed ID: 25233038
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
Trials; 2020 May; 21(1):415. PubMed ID: 32446298
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes in patients with cardiogenic shock according to left ventricular function: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme.
Aissaoui N; Riant E; Lefèvre G; Delmas C; Bonello L; Henry P; Bonnefoy E; Schiele F; Ferrières J; Simon T; Danchin N; Puymirat E;
Arch Cardiovasc Dis; 2018 Nov; 111(11):678-685. PubMed ID: 29290598
[TBL] [Abstract][Full Text] [Related]
11. Postconditioning in ST-elevation myocardial infarction: a systematic review, critical appraisal, and meta-analysis of randomized clinical trials.
Abdelnoor M; Sandven I; Limalanathan S; Eritsland J
Vasc Health Risk Manag; 2014; 10():477-91. PubMed ID: 25143742
[TBL] [Abstract][Full Text] [Related]
12. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.
Tea V; Bonaca M; Chamandi C; Iliou MC; Lhermusier T; Aissaoui N; Cayla G; Angoulvant D; Ferrières J; Schiele F; Simon T; Danchin N; Puymirat E;
Eur J Prev Cardiol; 2019 Mar; 26(4):411-419. PubMed ID: 30354737
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Outcomes with or without Beta-Blocker Therapy After Acute Myocardial Infarction in Patients Without Heart Failure or Left Ventricular Systolic Dysfunction (from the Acute Coronary Syndromes Israeli Survey [ACSIS]).
El Nasasra A; Beigel R; Klempfner R; Alnsasra H; Matetzky S; Iakobishvili Z; Rubinshtein R; Halabi M; Blatt A; Zahger D
Am J Cardiol; 2021 Mar; 143():1-6. PubMed ID: 33359228
[TBL] [Abstract][Full Text] [Related]
14. The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study.
Nicolau JC; Furtado RHM; Baracioli LM; Lara LM; Dalçóquio TF; Scanavini Junior MA; Pereira CAC; Lima VM; Gonçalves TM; Colodetti R; Ferrari AG; Lopes RD; Giugliano RP
Cardiovasc Drugs Ther; 2018 Oct; 32(5):435-442. PubMed ID: 30128818
[TBL] [Abstract][Full Text] [Related]
15. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
Park KL; Goldberg RJ; Anderson FA; López-Sendón J; Montalescot G; Brieger D; Eagle KA; Wyman A; Gore JM;
Am J Med; 2014 Jun; 127(6):503-11. PubMed ID: 24561113
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of β-blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis.
Konishi H; Miyauchi K; Kasai T; Tsuboi S; Ogita M; Naito R; Nishizaki Y; Okai I; Tamura H; Okazaki S; Isoda K; Daida H
Heart Vessels; 2016 Apr; 31(4):441-8. PubMed ID: 25573259
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior ST-Segment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction.
Shavadia JS; Youngson E; Bainey KR; Bakal J; Welsh RC
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673899
[TBL] [Abstract][Full Text] [Related]
18. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
Munkhaugen J; Ruddox V; Halvorsen S; Dammen T; Fagerland MW; Hernæs KH; Vethe NT; Prescott E; Jensen SE; Rødevand O; Jortveit J; Bendz B; Schirmer H; Køber L; Bøtker HE; Larsen AI; Vikenes K; Steigen T; Wiseth R; Pedersen T; Edvardsen T; Otterstad JE; Atar D
Am Heart J; 2019 Feb; 208():37-46. PubMed ID: 30530121
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.
Ruddox V; Sandven I; Munkhaugen J; Skattebu J; Edvardsen T; Otterstad JE
Eur J Prev Cardiol; 2017 Sep; 24(14):1555-1566. PubMed ID: 28617620
[TBL] [Abstract][Full Text] [Related]
20. Serum potassium levels and mortality of patients with acute myocardial infarction: A systematic review and meta-analysis of cohort studies.
Xi H; Yu RH; Wang N; Chen XZ; Zhang WC; Hong T
Eur J Prev Cardiol; 2019 Jan; 26(2):145-156. PubMed ID: 31060369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
